Published: Jun 09, 2021
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE)
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16
th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below.
Poster Presentation Title
: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies
Abstract Book Number: 236
Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CEST
Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia
Epigenetic endowment of every person has an impact on COVID-19 severity
COVID-19, caused by the infection of the SARS-CoV-2 virus, has changed people s behavioral patterns since the moment it became a global pandemic. To date, more than 136 million people have suffered from this disease, and more than 2.9 of these have lost their lives. The symptoms of the infection are varied, ranging from people with no clinical symptomatology to those who need hospital admission in the intensive care unit with the help from emergency assisted ventilation.
At the moment, the factors responsible for this wide range of clinical pictures are still unknown. Now, an article in
Genetic variants that impact protein binding in immune cells can cause autoimmune diseases
Apr 16 2021
Certain genetic variants that cause modified protein binding in immune cells, are also seen in those at high risk of some autoimmune diseases, new research has found.
Scientists from the Wellcome Sanger Institute, Josep Carreras Leukaemia Research Institute in Spain, and the MRC London Institute of Medical Sciences (LMS) found that certain genetic variants, which alter the binding ability of a protein called PU.1 in neutrophils, are also found to be associated with auto immune disease susceptibility.
This new study, published in
Nature Communications (16 April 2021), builds on previous research called BLUEPRINT. BLUEPRINT revealed how variation in blood cells’ characteristics and numbers can affect a person’s risk of developing complex diseases such as heart disease, and autoimmune diseases including rheumatoid arthritis, asthma, coeliac disease and type 1 diabetes.
Manel Esteller, professor of Genetics.
Aurora Pujol, IDIBELL researcher.
COVID-19, caused by the infection of the SARS-CoV-2 virus, has changed people’s behavioural patterns since the moment it became a global pandemic. To date, more than 136 million people have suffered from this disease, and more than 2.9 of these have lost their lives. The symptoms of the infection are varied, ranging from people with no clinical symptomatology to those who need hospital admission in the intensive care unit with the help from emergency assisted ventilation.
At the moment, the factors responsible for this wide range of clinical pictures are still unknown. Now, an article in EBioMedicine –The Lancet’s sister journal for laboratory findings– shows that the epigenetic endowment of every person has an impact on the severity of COVID-19. The study was carried out by the teams led by Manel Esteller, professor at the Department of Physiological Sciences of the UB, director of the Josep Carrera
Preliminary results from an ongoing study suggest that those with a certain blood type may have some protection against the novel coronavirus.
The coronavirus SARS-CoV-2 may latch more easily onto the airway cells of people with type A blood compared with those with type B or O blood, a new study suggests. The findings hint at a possible explanation for why, throughout the pandemic, studies have found those with type A blood are likelier to catch COVID-19 and develop severe symptoms than other blood types.
Laboratory experiments revealed that part of the coronavirus called the receptor binding domain (RBD), which directly binds to cells to jumpstart infection, also grabs onto unique molecules associated with type A blood. These molecules, known as antigens, show up on cells that line the respiratory tract, including the lungs, according to the study, published March 3 in the journal Blood Advances.